National Institute of Health (NIH) Awards Aracari Biosciences a Grant to Further Develop Proprietary Human Bone Marrow Technology That Models in Vivo Drug Responses
Aracari Biosciences, Inc. announces a grant award from the National Institute of Health (NIH) to further develop Aracari’s proprietary human bone marrow technology that models in vivo drug responses.
The most common adverse drug effect on the human bone marrow is compromised production of neutrophils, which is manifested clinically as neutropenia. The Aracari human bone marrow model (“VMBM”) has the unique ability to reproduce the bone marrow microenviroment and show neutrophils exiting the bone marrow and entering the peripheral blood circulation, thereby modeling the clinical signs of neutropenia.
Using small animals to model the human bone marrow’s response to chemotherapies or other drugs is resource intensive and can be misleading due to fundamental differences in leukocyte biology between humans and rodents. For example, neutrophils normally comprise 75%-90% of the leukocyte population in human peripheral blood, but only 10%-25% in mice.
“We are very excited that the NIH recognizes the power of Aracari’s bone marrow model to predict human responses to the wide array of drugs that either inhibit or stimulate human bone marrow,” shares Steven C. George, MD, PhD, Co-founder of Aracari Biosciences.